GSK Funded Study Confirms HPV Vaccine Cost-Effective in Chile

The Santiago Times

By Chris Noyce

July 15, 2009

Existing Vaccines Protect Against Two Most Common HPV Types In Chile

A study carried out by two Chilean universities into the causes of cervical cancer revealed that a national human papillomavirus (HPV) vaccination program in Chile would drastically reduce the number of cases of cervical-uterine cancer among women.

The study revealed that almost 87 percent of cases of cervical-uterine cancer in Chile can be linked to types 16 or 18 of HPV, a virus that infects the epidermis and mucous membranes of humans, potentially causing cancers of the cervix, vulva, vagina, and anus in women and cancers of the anus and penis in men.

The study analyzed the biopsies of 312 women with cervical-uterine cancer from three public hospitals in Chile in order to identify the types of virus that most commonly cause such cancer. It was carried out by doctors from the Universidad de la Frontera (UFRO) and the Universidad de Chile, and financed by pharmaceutical giant GlaxoSmithKline.

Eugenio Suárez, ontological gynecologist at Universidad de Chile and co-author of the study, confirmed that implementing a national vaccination program using either Cervarix or Gardasil would be cost-effective in reducing the number of women suffering from cervical-uterine cancer in Chile. He specifically noted it would lower the high number of cases resulting from types 16 and 18 of HPV in
On average, two women die from cervical-uterine cancer every day in Chile. It is the second-highest cause of death among women and the fifth most common type of cancer prevalent among Chilean women.

Two existing vaccines, Cervarix (created by GlaxoSmithKline) and Gardasil (created by Merck and Co.), offer protection against types 16 and 18. The current average cost for either of these vaccines ranges between US$440 and US$550.

Suárez also pointed out that in contrast to the Pap-smear test, a screening process used to detect premalignant and malignant cancerous processes in the cervix, a universal vaccine would also actively reduce the risk of pre-malignant processes occurring.

The study also revealed that as many as 93 percent of cervical-uterine cases in Chile can be traced to types 16, 18, 31, or 45 of HPV. Cervarix has been shown to offer some cross-reactive protection against types 31 and 45, which can also cause cancer.

Of the approximately 130 variations of HPV types that have been identified, between 30 and 40 are typically transmitted through sexual contact and infect the ano-genital area of the body.

A range of countries worldwide have implemented national vaccination programs against HPV.


Comment from Leslie

Study funded by GlaxoSmithKline? Lost all credibility for me…and the Big Pharma funded vaccine march goes on deeper and deeper into majority world countries without adequate tracking systems.


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.